IL18 and neoplasm: The TK/GCV system results in tumor mass reduction, and local secretion of IL-18 may maintain the Th1 immunity and tumor-specific cytotoxic T lymphocytes (CTLs) induced by the APCs that process tumor antigens from the apoptotic tumor cells killed by the TK/GCV system.